LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST), a leading acute care therapeutics company, today provided an overview of selected studies that will be presented at the 2011 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place from September 17th to 20th in Chicago. The studies focus on the company’s marketed antibiotic CUBICIN® (daptomycin for injection) and clinical antibiotic programs, CXA-201 and CB-183,315.
